Deals
EQT Offers to Buy Recipharm of Sweden in $2.1 Billion Deal
- Purchase follows wave of acquisitions in pharma industry
- Bid is a 23% premium to Friday’s closing share price
This article is for subscribers only.
Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions.
EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help pharmaceutical companies develop new drugs.